Oruka Therapeutics (NASDAQ:ORKA) Price Target Raised to $63.00

Oruka Therapeutics (NASDAQ:ORKA) had its price target hoisted by investment analysts at BTIG Research from $56.00 to $63.00 in a report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. BTIG Research’s price objective would indicate a potential upside of 131.11% from the company’s current price.

Other analysts also recently issued reports about the company. Barclays began coverage on Oruka Therapeutics in a research report on Monday, October 13th. They set an “overweight” rating and a $48.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Wednesday, October 8th. Wedbush restated an “outperform” rating and set a $40.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 12th. Guggenheim began coverage on shares of Oruka Therapeutics in a research note on Monday, October 27th. They issued a “buy” rating and a $60.00 price objective for the company. Finally, HC Wainwright reduced their price objective on Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Oruka Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $45.14.

Oruka Therapeutics Stock Down 3.7%

Shares of NASDAQ ORKA traded down $1.04 during trading hours on Thursday, hitting $27.26. The company had a trading volume of 88,684 shares, compared to its average volume of 293,560. The firm’s 50 day moving average is $22.16 and its 200-day moving average is $16.01. Oruka Therapeutics has a 1-year low of $5.49 and a 1-year high of $29.98. The stock has a market capitalization of $1.13 billion, a P/E ratio of -9.69 and a beta of -0.30.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.01. On average, sell-side analysts predict that Oruka Therapeutics will post -3.41 earnings per share for the current year.

Institutional Trading of Oruka Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ORKA. PNC Financial Services Group Inc. acquired a new position in shares of Oruka Therapeutics in the 3rd quarter worth approximately $39,000. Russell Investments Group Ltd. bought a new stake in Oruka Therapeutics during the third quarter valued at $43,000. Legal & General Group Plc acquired a new stake in Oruka Therapeutics during the 2nd quarter worth about $28,000. Ameritas Investment Partners Inc. bought a new position in shares of Oruka Therapeutics in the 2nd quarter worth about $31,000. Finally, BNP Paribas Financial Markets lifted its stake in shares of Oruka Therapeutics by 464.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after purchasing an additional 2,306 shares during the period. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.